Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00833989 · ClinicalTrials.gov registry record · Phase 2
Safety Escalating Repeat IV, in Stroke Patients
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00833989 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 42 participants.
The verdict
NCT00833989, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to is to test increasing repeat doses of GSK249320 compared to placebo in patients with stroke.
Interventions
- DRUG PLACEBO
- DRUG GSK249320
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2009-07-08 |
| Est. Completion | 2011-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00833989
The ClinicalTrials.gov registry entry for NCT00833989 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PLACEBO is the first listed.
NCT00833989 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00833989 about?
NCT00833989 is a clinical study titled "Safety Escalating Repeat IV, in Stroke Patients". The purpose of this study is to is to test increasing repeat doses of GSK249320 compared to placebo in patients with stroke.
What is the current status of trial NCT00833989?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2009-07-08. Estimated completion is 2011-01-31.
What interventions are being tested in trial NCT00833989?
The interventions under investigation include: PLACEBO (DRUG), GSK249320 (DRUG).
Who is sponsoring clinical trial NCT00833989?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.